BioCentury | Sep 29, 2016
Targets & Mechanisms

Hitting for the cycle

...and liver stages of the life cycle. Cipargamin is a synthetic spiroindolone analog that targets PfATP4...
...cytochrome B EEF2 - Eukaryotic translation elongation factor 2 P. falciparum phenylalanyl-tRNA synthetase PfATP4 - P. falciparum P-type cation-transporter ATPase 4...
BioCentury | Jan 15, 2015
Distillery Therapeutics

Therapeutics: P. falciparum P-type cation-transporter ATPase 4 (PfATP4)

...genome sequencing of mutant strains of the P. falciparum parasite resistant to the compound identified PfATP4...
...amodiaquine, to treat malaria infection. GlaxoSmithKline plc markets Malarone atovaquone for the same indication. TARGET/MARKER/PATHWAY: P. falciparum P-type cation-transporter ATPase 4 (PfATP4)...
BioCentury | Oct 20, 2014
Company News

Eisai, St. Jude Children's Research Hospital, Medicines for Malaria Venture deal

...and clinical testing of antimalarial compound SJ733. SJ733, a Plasmodium falciparum P-type cation-transporter ATPase 4 (PfATP4...
BioCentury | Aug 4, 2014
Clinical News

Cipargamin: Phase II data

...SIX:NOVN), Basel, Switzerland Product: Cipargamin ( KAE609 ) (formerly NITD609 ) Business: Infectious Molecular target: P. falciparum P-type cation-transporter ATPase 4 (PfATP4)...
Items per page:
1 - 4 of 4